Plasmid-Mediated KPC-2 in a
            <i>Klebsiella pneumoniae</i>
            Isolate from China

Wei, Zhenbo; Du, Xiaoxing; Yu, Yunsong; Shen, Ping; Chen, Yagang; Li, Lanjuan

doi:10.1128/aac.01053-06

Cited by 200 publications

(143 citation statements)

References 16 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…seems to be an emerging public health problem in various parts of the world [30,38], although, to date, widespread hospital outbreaks have been reported mainly in the United States [11,26,46,51,[63][64][65][66][67] and Israel [8,43].…”

Section: Discussionmentioning

confidence: 99%

“…Presently, KPC-1/2 carbapenemases have been reported among many species Gram-negative bacteria isolated in different countries of the world [8,[29][30][34][35][36][37][38][39]. Soon afterward, KPC-3 was founded in Klebsiella pneumoniae [39] and in other Enterobacteriaceae isolated in USA [11,[40][41][42].…”

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

“…First Klebsiella pneumoniae KPC-1/2 producing isolate in China was reported in 2007 [30]. Recently, in China, KPC-1/2 enzymes were reported in other species Enterobacteriaceae (Serratia marcescens, Escherichia coli and Citrobacter freundii) [31,32,33].…”

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

“…Outside of the United States the first case KPC-1/2 producing bacteria was reported in France [27], and more recently, cases were reported in Colombia [28,29], China [30] and in Israel [8]. First Klebsiella pneumoniae KPC-1/2 producing isolate in China was reported in 2007 [30].…”

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

“…The rapid spread of bla KPC genes can be attributed in part to their mobility and presence on plasmids or transposons [20,25,27,[30][31][32][33]35,[46][47][51][52][53][54]. The bla KPC genes have usually been identified in large plasmids.…”

Section: Molecular Characterization Of Bla Kpc Genes Encoded Kpc Carbmentioning

confidence: 99%

See 4 more Smart Citations

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

Sacha

Ostas²,

Jaworowska³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Antimicrobial resistance due to the continuous selective pressure from widespread use of antimicrobials in humans, animals and agriculture has been a growing problem for last decades. KPC β-lactamases hydrolyzed β-lactams of all classes. Especially, carbapenem antibiotics are hydrolyzed more efficiency than other β-lactam antibiotics. The KPC enzymes are found most often in Enterobacteriaceae. Recently, these enzymes have been found in isolates of Pseudomonas aeruginosa and Acinetobacter spp. The observations of bla KPC genes isolated from different species in other countries indicate that these genes from common but unknown ancestor may have been mobilized in these areas or that bla KPC -carrying bacteria may have been passively by many vectors. The emergence of carbapenem resistance in Gram-negative bacteria is worrisome because the carbapenem resistance often may be associated with resistance to many β-lactam and non-β-lactam antibiotics. Treatment of infections caused by KPC-producing bacteria is extremely difficult because of their multidrug resistance, which results in high mortality rates. Therapeutic options to treat infections caused by multiresistant Gram-negative bacteria producing KPC-carbapenemases could be used polymyxin B or tigecycline.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

Section: The Kpc -Enzymes: Characteristics and Epidemiologymentioning

confidence: 99%

Section: Molecular Characterization Of Bla Kpc Genes Encoded Kpc Carbmentioning

confidence: 99%

See 3 more Smart Citations

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

Sacha

Ostas²,

Jaworowska³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

The making of hypervirulent Klebsiella pneumoniae

Dai

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Klebsiella pneumoniae is a notorious bacterium in clinical practice. Virulence, carbapenem‐resistance and their convergence among K. pneumoniae are extensively discussed in this article. Hypervirulent K. pneumoniae (HvKP) has spread from the Asian Pacific Rim to the world, inducing various invasive infections, such as pyogenic liver abscess, endophthalmitis, and meningitis. Furthermore, HvKP has acquired more and more drug resistance. Among multidrug‐resistant HvKP, hypervirulent carbapenem‐resistant K. pneumoniae (Hv‐CRKP), and carbapenem‐resistant hypervirulent K. pneumoniae (CR‐HvKP) are both devastating for their extreme drug resistance and virulence. The hypervirulence of HvKP is primarily attributed to hypercapsule, macromolecular exopolysaccharides, or excessive siderophores, although it has many other factors, for example, lipopolysaccharides, fimbriae, and porins. In contrast with classical determination of HvKP, that is, animal lethality test, molecular determination could be an optional and practical method after improvement. HvKP, including Hv‐CRKP and CR‐HvKP, has been progressing. R‐M and CRISPR‐Cas systems may play pivotal roles in such evolutions. Hv‐CRKP and CR‐HvKP, in particular the former, should be of severe concern due to their being more and more prevalent.

show abstract

Nanodelivery strategies for the treatment of multidrug‐resistant bacterial infections

Jiang

Lin

Taggart

et al. 2018

J of Interdiscip Nanomed

View full text Add to dashboard Cite

One of the most important health concerns in society is the development of nosocomial infections caused by multidrug‐resistant pathogens. The purpose of this review is to discuss the issues in current antibiotic therapies and the ongoing progress of developing new strategies for the treatment of ESKAPE pathogen infections, which is acronymized for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. We not only examine the current issues caused by multidrug resistance but we also examine the barrier effects such as biofilm and intracellular localization exploited by these pathogens to avoid antibiotic exposure. Recent innovations in nanomedicine approaches and antibody antibiotic conjugates are reviewed as potential novel approaches for the treatment of bacterial infection, which ultimately may expand the useful life span of current antibiotics.

show abstract

Plasmid-Mediated KPC-2 in a Klebsiella pneumoniae Isolate from China

Cited by 200 publications

References 16 publications

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.

The making of hypervirulent Klebsiella pneumoniae

Nanodelivery strategies for the treatment of multidrug‐resistant bacterial infections

Contact Info

Product

Resources

About